Amgen Inc (AMGN)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Amgen Inc (AMGN)
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Key Insights
Critical company metrics and information
Share Price
$274.88Market Cap
$147.76 BillionTotal Outstanding Shares
537.53 Million SharesTotal Employees
26,700Dividend
$2.25 Per Share QuarterlyIPO Date
June 17, 1983SIC Description
Biological Products, (no Disgnostic Substances)Homepage
https://www.amgen.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Operating Activities, Continuing | $7.26 Billion |
Net Cash Flow From Financing Activities | $-5.25 Billion |
Net Cash Flow From Financing Activities, Continuing | $-5.25 Billion |
Net Cash Flow From Investing Activities, Continuing | $-27.73 Billion |
Net Cash Flow | $-25.73 Billion |
Net Cash Flow, Continuing | $-25.73 Billion |
Net Cash Flow From Investing Activities | $-27.73 Billion |
Net Cash Flow From Operating Activities | $7.26 Billion |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Income/Loss Available To Common Stockholders, Basic | $4.23 Billion |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Other Operating Expenses | $5.97 Billion |
Nonoperating Income/Loss | $1.69 Billion |
Operating Income/Loss | $6.22 Billion |
Diluted Earnings Per Share | $7.83 |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Diluted Average Shares | $1.08 Billion |
Income Tax Expense/Benefit | $449.00 Million |
Revenues | $32.53 Billion |
Net Income/Loss | $4.23 Billion |
Selling, General, and Administrative Expenses | $7.49 Billion |
Costs And Expenses | $26.32 Billion |
Income/Loss From Equity Method Investments | $-17.00 Million |
Gross Profit | $19.68 Billion |
Income/Loss Before Equity Method Investments | $4.68 Billion |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Income/Loss From Continuing Operations After Tax | $4.23 Billion |
Basic Earnings Per Share | $7.89 |
Net Income/Loss Attributable To Parent | $4.23 Billion |
Cost Of Revenue | $12.86 Billion |
Operating Expenses | $13.46 Billion |
Income/Loss From Continuing Operations Before Tax | $4.68 Billion |
Basic Average Shares | $1.07 Billion |
Benefits Costs and Expenses | $27.86 Billion |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Noncurrent Liabilities | $63.04 Billion |
Liabilities | $83.36 Billion |
Intangible Assets | $28.92 Billion |
Current Liabilities | $20.31 Billion |
Other Non-current Liabilities | $2.65 Billion |
Equity | $7.53 Billion |
Equity Attributable To Parent | $7.53 Billion |
Inventory | $7.36 Billion |
Long-term Debt | $60.40 Billion |
Liabilities And Equity | $90.88 Billion |
Other Current Assets | $19.40 Billion |
Other Non-current Assets | $29.04 Billion |
Equity Attributable To Noncontrolling Interest | $0.00 |
Current Assets | $26.77 Billion |
Other Current Liabilities | $18.16 Billion |
Noncurrent Assets | $64.12 Billion |
Assets | $90.88 Billion |
Accounts Payable | $2.15 Billion |
Fixed Assets | $6.16 Billion |
Historical Dividends
Current dividend: $2.25 Per Share Quarterly
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
Oct 25, 2024 | Dec 9, 2024 | Nov 18, 2024 | $2.25 | Quarterly |
Aug 2, 2024 | Sep 6, 2024 | Aug 16, 2024 | $2.25 | Quarterly |
Mar 6, 2024 | Jun 7, 2024 | May 17, 2024 | $2.25 | Quarterly |
Dec 12, 2023 | Mar 7, 2024 | Feb 16, 2024 | $2.25 | Quarterly |
Oct 24, 2023 | Dec 8, 2023 | Nov 17, 2023 | $2.13 | Quarterly |
Aug 1, 2023 | Sep 8, 2023 | Aug 18, 2023 | $2.13 | Quarterly |
Mar 7, 2023 | Jun 8, 2023 | May 18, 2023 | $2.13 | Quarterly |
Dec 12, 2022 | Mar 8, 2023 | Feb 15, 2023 | $2.13 | Quarterly |
Oct 28, 2022 | Dec 8, 2022 | Nov 17, 2022 | $1.94 | Quarterly |
Aug 3, 2022 | Sep 8, 2022 | Aug 18, 2022 | $1.94 | Quarterly |
Mar 2, 2022 | Jun 8, 2022 | May 17, 2022 | $1.94 | Quarterly |
Dec 3, 2021 | Mar 8, 2022 | Feb 15, 2022 | $1.94 | Quarterly |
Oct 21, 2021 | Dec 8, 2021 | Nov 16, 2021 | $1.76 | Quarterly |
Jul 30, 2021 | Sep 8, 2021 | Aug 17, 2021 | $1.76 | Quarterly |
Mar 3, 2021 | Jun 8, 2021 | May 17, 2021 | $1.76 | Quarterly |
Dec 16, 2020 | Mar 8, 2021 | Feb 15, 2021 | $1.76 | Quarterly |
Oct 21, 2020 | Dec 8, 2020 | Nov 16, 2020 | $1.6 | Quarterly |
Jul 23, 2020 | Sep 8, 2020 | Aug 17, 2020 | $1.6 | Quarterly |
Mar 4, 2020 | Jun 8, 2020 | May 18, 2020 | $1.6 | Quarterly |
Dec 11, 2019 | Mar 6, 2020 | Feb 14, 2020 | $1.6 | Quarterly |
Oct 22, 2019 | Dec 6, 2019 | Nov 15, 2019 | $1.45 | Quarterly |
Aug 2, 2019 | Sep 6, 2019 | Aug 15, 2019 | $1.45 | Quarterly |
Mar 7, 2019 | Jun 7, 2019 | May 17, 2019 | $1.45 | Quarterly |
Dec 7, 2018 | Mar 8, 2019 | Feb 15, 2019 | $1.45 | Quarterly |
Oct 23, 2018 | Dec 7, 2018 | Nov 16, 2018 | $1.32 | Quarterly |
Jul 31, 2018 | Sep 7, 2018 | Aug 17, 2018 | $1.32 | Quarterly |
Mar 7, 2018 | Jun 8, 2018 | May 17, 2018 | $1.32 | Quarterly |
Dec 12, 2017 | Mar 8, 2018 | Feb 15, 2018 | $1.32 | Quarterly |
Oct 24, 2017 | Dec 8, 2017 | Nov 17, 2017 | $1.15 | Quarterly |
Jul 28, 2017 | Sep 8, 2017 | Aug 17, 2017 | $1.15 | Quarterly |
Mar 7, 2017 | Jun 8, 2017 | May 17, 2017 | $1.15 | Quarterly |
Dec 20, 2016 | Mar 8, 2017 | Feb 15, 2017 | $1.15 | Quarterly |
Oct 14, 2016 | Dec 8, 2016 | Nov 16, 2016 | $1 | Quarterly |
Jul 22, 2016 | Sep 8, 2016 | Aug 17, 2016 | $1 | Quarterly |
Mar 2, 2016 | Jun 8, 2016 | May 17, 2016 | $1 | Quarterly |
Dec 15, 2015 | Mar 8, 2016 | Feb 16, 2016 | $1 | Quarterly |
Oct 14, 2015 | Dec 7, 2015 | Nov 16, 2015 | $0.79 | Quarterly |
Jul 28, 2015 | Sep 8, 2015 | Aug 17, 2015 | $0.79 | Quarterly |
Mar 4, 2015 | Jun 5, 2015 | May 14, 2015 | $0.79 | Quarterly |
Dec 17, 2014 | Mar 6, 2015 | Feb 12, 2015 | $0.79 | Quarterly |
Oct 17, 2014 | Dec 5, 2014 | Nov 13, 2014 | $0.61 | Quarterly |
Jul 25, 2014 | Sep 5, 2014 | Aug 14, 2014 | $0.61 | Quarterly |
Mar 5, 2014 | Jun 6, 2014 | May 15, 2014 | $0.61 | Quarterly |
Dec 13, 2013 | Mar 7, 2014 | Feb 13, 2014 | $0.61 | Quarterly |
Jul 26, 2013 | Sep 6, 2013 | Aug 16, 2013 | $0.47 | Quarterly |
Mar 6, 2013 | Jun 7, 2013 | May 16, 2013 | $0.47 | Quarterly |
Dec 13, 2012 | Mar 7, 2013 | Feb 13, 2013 | $0.47 | Quarterly |
Oct 10, 2012 | Dec 7, 2012 | Nov 15, 2012 | $0.36 | Quarterly |
Related Companies
View additional S&P 500 companies similar to Amgen Inc (AMGN)
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.